ORUM Net Assets
ORUM net assets. Based on the latest financial reports, ORUM (475830) has net assets worth ₩119.57 Billion KRW (≈ $81.03 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩312.82 Billion ≈ $211.99 Million USD) and total liabilities (₩193.25 Billion ≈ $130.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of ORUM to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩119.57 Billion |
| % of Total Assets | 38.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of ORUM (2022–2025)
Net assets of ORUM from 2022 to 2025. This chart illustrates how ORUM's net assets have evolved over time, based on quarterly financial data. See ORUM (475830) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for ORUM (2022–2025)
The table below shows the annual net assets of ORUM from 2022 to 2025. For live market cap and overall valuation, see ORUM (475830) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩130.89 Billion ≈ $88.70 Million |
+7.49% |
| 2024-12-31 | ₩121.76 Billion ≈ $82.52 Million |
+316.74% |
| 2023-12-31 | ₩-56.18 Billion ≈ $-38.07 Million |
+55.92% |
| 2022-12-31 | ₩-127.46 Billion ≈ $-86.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ORUM's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15050789604000.0% over the analyzed period, indicating profitable operations and earnings retention.
ORUM Net Assets Breakdown (December 2025)
ORUM net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩18.22 Billion | 13.92% |
| Other Components | ₩112.67 Billion | 86.08% |
| Total Equity | ₩130.89 Billion | 100.00% |
ORUM Competitors by Market Cap
The table below lists competitors of ORUM ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Utah Medical Products Inc
NASDAQ:UTMD
|
$216.74 Million |
|
Silver Storm Mining Ltd.
V:SVRS
|
$216.75 Million |
|
Wei Chuan Foods Corp
TW:1201
|
$216.84 Million |
|
HengFeng Information Technology Co Ltd
SHE:300605
|
$217.01 Million |
|
Jaya Tiasa Holdings Bhd
KLSE:4383
|
$216.39 Million |
|
Shanghai Chlor-Alkali Chemical Co Ltd B
SHG:900908
|
$216.29 Million |
|
BRC Inc.
NYSE:BRCC
|
$216.27 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
$216.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORUM's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 121,764,729,720 to 130,888,052,360, a change of 9,123,322,640 (7.5%).
- Net loss of 41,969,171,950 reduced equity.
- New share issuances of 49,566,873,770 increased equity.
- Other factors increased equity by 1,525,620,820.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-41.97 Billion | -32.06% |
| Share Issuances | ₩49.57 Billion | +37.87% |
| Other Changes | ₩1.53 Billion | +1.17% |
| Total Change | ₩- | 7.49% |
Book Value vs Market Value Analysis
This analysis compares ORUM's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.44x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩-6090.15 | ₩15060.00 | x |
| 2023-12-31 | ₩-2684.29 | ₩15060.00 | x |
| 2024-12-31 | ₩5817.96 | ₩15060.00 | x |
| 2025-12-31 | ₩6164.55 | ₩15060.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ORUM utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -178105.42%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-32.06%) is below the historical average (-9.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -83402.58% | 0.00x | 0.00x | ₩-50.57 Billion |
| 2023 | 0.00% | 50.38% | 0.84x | 0.00x | ₩73.84 Billion |
| 2024 | -4.71% | -27.46% | 0.14x | 1.26x | ₩-17.92 Billion |
| 2025 | -32.06% | -178105.42% | 0.00x | 1.29x | ₩-55.06 Billion |
Industry Comparison
This section compares ORUM's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $287,302,015,827
- Average return on equity (ROE) among peers: -9.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORUM (475830) | ₩119.57 Billion | 0.00% | 1.62x | $216.70 Million |
| ORIENTBIO Inc. (002630) | $62.29 Billion | 1.41% | 1.19x | $94.35 Million |
| Green Cross (005250) | $895.76 Billion | 3.06% | 4.14x | $285.63 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $82.42 Billion | -31.18% | 0.21x | $361.91 Million |
| GeneOne Life Science Inc (011000) | $24.06 Billion | -31.66% | 1.13x | $32.81 Million |
| HLB Co. Ltd (028300) | $46.46 Billion | 0.00% | 0.75x | $3.66 Billion |
| Mgenplus Co. Ltd. (032790) | $11.48 Billion | -51.58% | 1.56x | $19.35 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $43.14 Billion | 6.18% | 0.41x | $21.71 Million |
| Hyundai Bioscience Co. Ltd (048410) | $14.17 Billion | 0.00% | 1.15x | $342.04 Million |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more